In addition, out of 32 patients changed to azapropazone who were receiving additional analgesics at the start of the study, 22 were able to stop this analgesic(s), 10 continued them, and five more had to start taking-usually intermittently-additional analgesics. Of 39 patients who continued taking allopurinol, nine were able to stop additional analgesics, nine continued on the same additional analgesics as before, and 21 had to start treatment with an additional analgesic.
Thus, azapropazone would appear to be a useful alternative drug for the long term control of patients with chronic gout or hyperuricaemia, or both. Its two possible important advantages are that it is a single drug 
